Pharsight

Tigecycline generic

tigecycline is an intravenous powder owned by Amneal. The drug got its first market authorization on August 2, 2018. The active ingredient is tigecycline granting its unique properties.

When will Tigecycline generic be available?

The generic version of Tigecycline will be possible after April 7, 2033. This is due to the expiry of the last patent, US9855335 titled 'Tigecycline composition for injection'.

Tigecycline uses

tigecycline, the active ingredient in tigecycline, makes it potent as it can be used for therapeutic treatments requiring intravenous administration.

Tigecycline patent expiration

Tigecycline holds a total of 1 patent, none of which have expired. The last patent for Tigecycline generic (US9855335) will expire on April 7, 2033. Below are the details of the patent:

Tigecycline dosage

Want to ask something?